Keyphrases
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
100%
Breast Cancer
38%
Human Epidermal Growth Factor Receptor 2 (HER2)
37%
Anthracyclines
36%
Breast Cancer Patients
34%
Cell Association
33%
Cyclophosphamide
29%
Fluorouracil
29%
Ki-67
26%
Immunoreactivity
22%
Methotrexate
21%
Cooperative Group
19%
Matrix metalloproteinase-9 (MMP-9)
16%
Alpha Inhibitors
16%
Breast Cancer Risk
16%
Breast Cancer Treatment
16%
Sentinel Lymph Node
16%
Stroma Cells
16%
Randomized Phase III Trial
16%
Advanced Breast Cancer
16%
Kidney Pelvis
16%
Colorectal Cancer Cells
16%
Gemcitabine
16%
Intermediate Risk
16%
Patient Outcomes
16%
Micrometastasis
16%
Predictive Role
16%
Topoisomerase IIα
16%
Overall Survival
15%
Pharmacology, Toxicology and Pharmaceutical Science
Tissue Inhibitor of Metalloproteinase 1
83%
Breast Cancer
51%
Fluorouracil
34%
Colorectal Carcinoma
34%
Neoplasm
34%
Gelatinase B
33%
Anthracycline
33%
Cyclophosphamide
29%
Overall Survival
28%
Methotrexate
21%
Recurrence Free Survival
20%
Malignant Neoplasm
17%
Micrometastasis
16%
Gemcitabine
16%
Early Growth Response Factor 1
16%
Glioblastoma
16%
Bladder Cancer
16%
Tissue Inhibitor of Metalloproteinase
16%
Cancer Chemotherapy
16%
Peroxisome Proliferator Activated Receptor Alpha
16%
Peroxisome Proliferator Activated Receptor
16%
Disease Exacerbation
16%
Medicine and Dentistry
Breast Cancer
17%
Peroxisome Proliferator Activated Receptor
16%
Sentinel Node
16%
Early Growth Response Factor 1
16%
Urothelium
16%
Kidney Pelvis
16%
Glioblastoma
16%
Micrometastasis
16%
Metalloprotease Inhibitor
16%
Tissue Inhibitor of Metalloproteinase 1
16%
Metastatic Carcinoma
16%
Bladder
16%
